Company profile: NICO
1.1 - Company Overview
Company description
- Provider of medical devices for minimally invasive neurosurgery and skull base and spinal procedures, including BrainPath for access to the subcortical space; Myriad SPECTRA for automated brain tumor removal and clot evacuation with directional light for fluorescence guidance; APS for intraoperative tissue collection and preservation; and meniGLIDE for controlled meningeal opening.
Products and services
- Myriad SPECTRA: A multifunctional hand-held device for automated brain tumor removal and clot evacuation, featuring directional light for fluorescence-guided surgery
- BrainPath: Delivers minimally disruptive, navigable access to the subcortical space for neurosurgical procedures, preserving brain tissue and vasculature
- Automated Preservation System (APS): A system for intraoperative tissue collection and preservation, minimizing tissue degradation and maintaining biological conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NICO
Lineagen
HQ: United States
Website
- Description: Provider of diagnostic and healthcare services for complex genetic diseases, offering FirstStepDx PLUS chromosomal microarray to identify genomic deletions/duplications associated with autism spectrum disorder, developmental delay, intellectual disability, congenital anomalies, dysmorphic features, and epilepsy; NextStepDx PLUS whole exome sequencing; genetic counseling; and optical genome mapping data services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lineagen company profile →
Vico Therapeutics
HQ: The Netherlands
Website
- Description: Provider of RNA-modulating therapies for rare neurological/CNS disorders, focused on SCA, HD and RTT. Offers VO659, an antisense oligonucleotide targeting CAG repeat expansions in polyglutamine diseases (Spinocerebellar Ataxia types 1/3 and Huntington’s) to reduce mutant protein levels and improve motor function, and VICOMER, a platform designing RNA therapeutics via translation, splicing, editing, degradation and activation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vico Therapeutics company profile →
Protembis
HQ: Germany
Website
- Description: Provider of a catheter-based cerebral protection system (ProtEmbo) that deflects embolic material away from the cerebrovascular circulation during left-sided heart procedures, particularly transcatheter aortic valve replacement (TAVR).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protembis company profile →
Envoy Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envoy Therapeutics company profile →
Alkermes
HQ: Ireland
Website
- Description: Provider of medicines for prevalent, chronic diseases, developing, manufacturing and commercializing VIVITROL for alcohol dependence and RISPERDAL CONSTA for schizophrenia; advancing pipeline candidates including olanzapine and samidorphan for pediatric schizophrenia and bipolar I (Phase 3), ALKS 2680 for narcolepsy types 1 and 2 (Phase 2), and orexin agonists for neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alkermes company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NICO
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NICO
2.2 - Growth funds investing in similar companies to NICO
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NICO
4.2 - Public trading comparable groups for NICO
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →